Overview of CHAMPION MG Clinical Study in Generalized Myasthenia Gravis
The CHAMPION MG study is a phase 3 study investigating the safety and effectiveness of a potential treatment for MG, ravulizumab-cwvz. The trial will include 160 MG patients in multiple centers worldwide.
With MG, certain antibodies of the immune system mistakenly attack normal cells as if they were infections. These antibodies activate an overstimulated pathway in the immune system, called the complement pathway, that affects the area where nerve-to-muscle communication happens.